These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16972162)

  • 1. Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI.
    Kleinman L; Kilburg A; Machnicki G; Faull R; Walker R; Prasad R; Ambuehl P; Bahner U; Margolis MK
    Qual Life Res; 2006 Sep; 15(7):1223-32. PubMed ID: 16972162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal (GI)-Specific patient reported outcomes instruments differentiate between renal transplant patients with or without GI symptoms: results from a South American cohort.
    Machnicki G; Pefaur J; Gaite L; Linchenco AM; Raimondi C; Schiavelli R; Otero A; Margolis MK
    Health Qual Life Outcomes; 2008 Jul; 6():53. PubMed ID: 18644133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastrointestinal-specific patient-reported outcome instruments differentiate between renal transplant patients with or without GI complications.
    Kleinman L; Faull R; Walker R; Ramesh Prasad GV; Ambuehl P; Bahner U
    Transplant Proc; 2005 Mar; 37(2):846-9. PubMed ID: 15848552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Chan L; Mulgaonkar S; Walker R; Arns W; Ambühl P; Schiavelli R
    Transplantation; 2006 May; 81(9):1290-7. PubMed ID: 16699457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M; Settmacher U; Ganten T; Sarrazin C; Speidel N; Broering D; Heyne N; Paulus E; Mertens M; Fischer L
    Transplant Proc; 2014; 46(1):234-40. PubMed ID: 24507058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastrointestinal symptoms impair quality of life in Italian renal transplant recipients but are under-recognized by physicians.
    Ponticelli C; Colombo D; Novara M; Basilisco G;
    Transpl Int; 2010 Nov; 23(11):1126-34. PubMed ID: 20525020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P; Vijayaraghavan R; Thiagarajan CM; Sharma RK; Subbarao B; Pishardy R; Dakshinamurthy KV; Vijaykumar R; Abraham G; Bhaskar S; Agarwal L; Shah B; Abraham A; John M; Sampathkumar K; Das T; Umesh L; Sundar S; Ballal H; Jasuja S; Saxena S; Saha TK
    Transplant Proc; 2008 Sep; 40(7):2262-7. PubMed ID: 18790208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F; Sánchez-Fructuoso A; Cruzado JM; Gómez-Alamillo JC; Alarcón A; Pallardó L; Morales JM; Oliver J; Guinea G;
    Transplantation; 2011 Aug; 92(4):426-32. PubMed ID: 21760569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients.
    Toledo AH; Hendrix L; Buchholz V; Fisher E; Newton K; Smith C; Gerber DA
    Clin Transplant; 2012; 26(1):156-63. PubMed ID: 21470310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients.
    Bolin P; Tanriover B; Zibari GB; Lynn ML; Pirsch JD; Chan L; Cooper M; Langone AJ; Tomlanovich SJ
    Transplantation; 2007 Dec; 84(11):1443-51. PubMed ID: 18091520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of a specific questionnaire for evaluating the impact of gastrointestinal symptoms on the health-related quality of life of transplant patients.
    Ortega F; Bravo J; Cantarell C; Cofán F; Gómez-Bravo MA; Miras M; Crespo-Leiro MG; Ussetti P; Guinea G
    Transplant Proc; 2012 Jun; 44(5):1281-6. PubMed ID: 22664001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms of UGT1A8, UGT1A9 and HNF-1α and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Vu D; Tellez-Corrales E; Yang J; Qazi Y; Shah T; Naraghi R; Hutchinson IV; Min DI
    Transpl Immunol; 2013 Dec; 29(1-4):155-61. PubMed ID: 23721685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients.
    Ekberg H; Kyllönen L; Madsen S; Grave G; Solbu D; Holdaas H
    Transplantation; 2007 Feb; 83(3):282-9. PubMed ID: 17297402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF; Montambault P; Wolff JL; Lemire J; Masse M
    Transplant Proc; 2009 Nov; 41(9):3683-9. PubMed ID: 19917367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphisms of MRP2 and UGT2B7 and gastrointestinal symptoms in renal transplant recipients taking mycophenolic acid.
    Yang JW; Lee PH; Hutchinson IV; Pravica V; Shah T; Min DI
    Ther Drug Monit; 2009 Oct; 31(5):542-8. PubMed ID: 19730281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of gastrointestinal complications in renal graft recipients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Reinke P; Budde K; Hugo C; Petersen P; Schnuelle P; Fricke L; Scholz D; Sperschneider H; Bahner U; Kramer S; Fischer W; Arns W
    Transplant Proc; 2011 Jun; 43(5):1641-6. PubMed ID: 21693250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric validation of the Hungarian translation of the gastrointestinal symptom rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with reflux disease.
    Kulich RK; Ujszászy L; Tóth GT; Bárány L; Carlsson J; Wiklund I
    Orv Hetil; 2004 Mar; 145(13 Suppl 2):723-9, 739-44. PubMed ID: 15125325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Psychometric validation of the Polish translation of the Gastrointestinal Symptom Rating Scale (GSRS) and Quality of Life in Reflux and Dyspepsia (QOLRAD) Questionnaire in patients with reflux disease].
    Kulich KR; Reguła J; Stasiewicz J; Jasinski B; Carlsson J; Wiklund I
    Pol Arch Med Wewn; 2005 Mar; 113(3):241-9. PubMed ID: 16128281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
    Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.